PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Expected to Announce Quarterly Sales of $5.83 Million

Brokerages predict that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) will report $5.83 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for PhaseBio Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $9.17 million. The business is scheduled to report its next earnings results on Monday, January […]

Related Keywords

,Financial Consultants Inc ,Investment Advisors ,Phasebio Pharmaceuticals Inc ,Phasebio Pharmaceuticals Get Rating ,Zacks Investment Research ,Blackrock Inc ,Nasdaq ,Needham Company ,Marshall Wace ,Phasebio Pharmaceuticals ,Citadel Advisors ,Get Rating ,Phasebio Pharmaceutical ,Bio Pharmaceuticals ,Northeast Financial Consultants Inc ,Nasdaq Phas ,Kephas ,Medical ,Ratings ,Consensus ,